Neos Therapeutics develops, manufactures, and commercializes innovative extended-release products using our proprietary extended-release drug delivery and orally disintegrating tablet technology platforms. They have two FDA approved products for the treatment of ADHD and both utilize their extended-release ODT technology. Their third branded ADHD product candidate is an extended-release oral suspension. Their growing ADHD Product Portfolio puts Neos in a unique position to help meet the different needs of patients that struggle with ADHD.